Thehaematopoietic hormone erythropoietin (EPO) hasneuroprotectivepropertiesand is currentlybeing exploredfor treatment of strokea nd othern eurological disorders. Short-term, high-dose treatment with EPO seems to improven eurological function of strokepatientsbut maybeassociated with increased thromboticrisk, whereas alternative non-erythropoietic neuroprotectived erivatives of EPO,s uch as carbamylatedE PO (CEPO), maybedevoid of such side-effects.We investigatedthe effects of short-term, high-dose treatment with EPO and CEPO on plateletf unctiona nd haemostasisi nh ealthym ice and rats. Animals received three daily dosesofEPO or CEPO (50 µg/kg), and blood was compared with respecttoalterations in haematology and plateletr eactivity.Inr ats, treatment with EPO increasedthe haematocrit to >50% and the mean plateletvolume by 37%,while CEPOhad no effect on these parameters.Platelets Keywords ADP, collagen, P-selectin, MPV,stroke from EPO-treatedr ats showeda ni ncreaseds ensitivity to thrombin receptor agonist peptidesand elevatedplasma levels of soluble P-selectin (sP-selectin) were found in treatedm ice. Furtheri ndicators of plateleth yperreactivity in EPO,but not CEPO-treatedanimals, were significantlyincreasedaggregatory responsest oc ollageni nw holeb looda nd platelet-rich plasma (PRP).The increasedp lateletr eactivity was paralleledb yad ecreasedbleeding timeafter tail transection in rats.Samples from EPO-treatedr ats showeda na ttenuatedr esponset oADP in whole blood aggregometryand thrombelastography(TEG) plateletmapping but not in apyrase-treatedPRP,suggesting involvement of ADP receptor desensitization. Thesef indingss uggest that while EPO affects various aspects of plateletf unction, CEPOisdevoid of such effects.
Introduction
The cytokineerythropoietin (EPO) is the primary stimulator of erythropoiesis, and recombinant humanEPO (rhEPO)iswidely used in the treatment of anaemia (1) .Additionally, EPOhas attracted interest as aneuroprotectiveagent with therapeutic potential in diseases such as stroke, traumatic brain injury, schizophreniaand spinal cordinjury (2) . In small clinicaltrials,EPO seemstoexert beneficial effectsinstrokepatients (3) as well as in schizophrenicpatients (4) . These studiessuggest that EPO or EPO derivativesmay be relevant for future treatment of patients suffering from av arietyo fc entral nervous system (CNS) disorders. However, treatment with EPO hasbeen linked to an increased risk of thrombotic events, and EPOseemstoaffect variouscardiovascularand haemostatic parametersunrelated to increases in haematocrit (5, 6) . Fori nstance, EPO treatment improvescompromised plateletfunction in patients with renal failureindependentlyofincreases in haematocrit (7) .Indogs, EPO induces afunctional hyperreactivity of platelets, and potentiates thrombus development in amodel of arteriovenous shunting (8, 9) . EPO mayalso be pro-thrombotic in humans, both by increasing plateletr eactivity and by causing an increase in systemic blood pressure through vasoconstriction (5,1 0). These prothromboticp ropertieso fE PO appear clinically relevant, since threetrials evaluating EPO treatment in cancer patients were prematurelyterminateddue to increased thromboticand cardiovascular events ( 6) . In the strokep opulation, haemostatic side-effects of EPO areparticularlyundesirable, giventhe severe haemostatic disturbances in these patients (11) .
Thepotential pro-thromboticeffectsofEPO in treatment of anaemic patients have alreadybeen evaluated; however, for correction of anaemia,patients typically receive chronic treatment with lowdoses of EPO (i.e.~50-100 U/kg =0.5-1 µg/kg, three times weekly, [12] ). In contrast, little is known about the adverse effectsofshort-termhigh-doseEPO treatment, whichisrelevant for neuroprotection. Fore xample, beneficial effectsi na nimal models of strokeare obtainedwith 1-3 doses of 5-50 µg/kg EPO.
Non-erythropoietic derivativesofEPO,which do not bind to the classical EPO receptor,may have fewerunwantedhaemostatic effects; however, this remains to be evaluated. Them ost studied EPO-derivative is carbamylated EPO( CEPO), which actsn europrotectivelyi nav arietyo fd ifferent animalm odels, such as cerebrali schemia (13, 14) ,a utoimmune encephalomyelitis (13) , spinalcord injury (13) and motor neuron degeneration (15) . Giventhe potential use of EPO and CEPOastherapeutics for CNS indications, an evaluation of the thrombotic risksa ssociatedw ith high-dose, short-term EPOa nd CEPO treatment is warranted.
In this study, we testedthe hypothesis that short-termhighdosetreatment with EPO affectshaematological parameters including plateletfunction, whereas CEPO hasnoeffect on these parameters. Thus,miceand rats were treated with EPO,CEPOor saline using adosing protocol compatible with protocols tested in acute ischemic strokestudies. Haematological parameters and plasma levels of solubleP -selectin( sP-selectin) were determinedaswellasagonist-induced plateletreactivity investigated by flow cytometry, whole blood aggregometry, platelet-rich plasma (PRP)a ggregometrya nd thrombelastography( TEG) platelet mapping. Plasmaprotein levels were analysed by Westernb lotting and the in vivo consequences of EPOa nd CEPO treatment were evaluatedasbleeding time in the rat tail transection model.
Materials andmethods

Materials
EPOf rom DragonP harmaceuticals (Vancouver,C anada) was used for all experiments. Forstudiesonhaematological parameters ( Fig. 1) ,p arallele xperiments were runw ith Epoetin beta (NeoRecormon ® ,F .Hoffmann-La Roche Ltd). CEPOwas synthesizedfrom EPOasdescribed earlier (13) . Identityand purity of the material as well as batch-identity wasv erified by amino group titration, digest with LysC and peptide fragment analysis by mass spectrometrya sd escribed elsewhere (13) .The CEPO batchusedinthese experiments has beenverified forneuroprotectiveactivity in animalmodels (unpublished data). The mouse thrombin receptor PA R-3(SFNGGP)and PA R-4(GYPGKF)activating peptidesw ere synthesizedatNovoNordisk (Denmark) using standard peptide chemistry.
Animalsand treatments
Allexperimentalprocedures were carriedout in accordancewith the directiveso ft he DanishN ationalC ommitteeo nAnimal Research Ethics andt he European Communities Council Directive #86/609 for careo fl aboratorya nimals. Animalsw ereo btained from Charles River, Germany. MaleNMRI mice weighing 25-30g were doseds ubcutaneously with av olumeo f1 0m l/kg.A lternatively,S prague-Dawleyr ats weighing 200-250gw ered osed with avolumeof1ml/kg.Animals were dosedoncedailywith EPO (50µg/kg),CEPO (50µg/kg) or saline (0.9%NaCl) for 1-3 days. Forexperiments with mice receiving doses lowerthan50µg/kg, a protein-stabilising vehicle wasu sed (0.9% NaCl +0 .1% human serum albumin). Allanimals were euthanized after experiments.
Analysis of haematological parameters
Rats and micewere anaesthetized with isoflurane and blood was drawn from the vena cava withS -Monovette K-EDTA tubes (Sarstedt,Germany). Haematological parameters were analysed immediately on ADVIA ® 120 (Bayer, Germany) usingm ulti species software3.1 (Bayer).
P-selectinflowcytometry
Rats were anaesthetized with Avertin and blood wasc ollected with S-Monovette citratet ubes by cardiacp uncture. Citrated blood (50 µl) wasi ncubated with different concentrations of mouse thrombin receptor PA R-3( SFNGGP)a nd PA R-4 (GYPGKF)agonist peptides for 5minutes(min) at 37 o C. Antibodies CD62-PE( Biotex,L Y20, 3µ l) and CD61-FITC (BD 553346,4µl) were added and incubatedfor 30 min at room temperature. Red blood cells (RBC)w ere lysedbyincubating with 1mlred blood cell (RBC)l ysing buffer (BDBioscienceF ACS lysing solution, 349202, San Jose,CA, USA) for 10 minatroom temperaturebefore centrifugation for 5min at 200xg.The pellet waswashed with 2mlwashing buffer (20mMHepes pH 7.4, 150mMNaCl, 1mg/ml bovine serum albumin [BSA] ) and centrifugedfor 5min at 200xg.FACSflow(BD Bioscience, 0.5ml) wasa dded to the pellet and samples were analysed on a FACSCanto flow cytometer(BD Bioscience).Forwardand side scatter light channels and fluorescence channels were set on log. Ag atew as setonCD61 positivecells (all platelets), and %of cells within this gate positive for P-selectin (CD62P) wasdetermined. Single coloured activatedp latelets were used for compensation of overlapping fluorescence signals.
sP-selectinELISA
Mice were anaesthetized with Avertin and blood wasc ollected from the heart into S-Monovette tubesc ontaining am ix of citrate, theophylline,a denosine,a nd dipyridamole (CTAD). Samples were immediately placed on ice and platelet-poor plasma wasprepared by tworounds of centrifugation (2,500 xgfor 20 min). Foreach roundthe middle1/3 of the plasma phase was isolatedfor further procedure. Plasma samples were analysed by the mousesP-selectin ELISAkit from R&D systems (Minneapolis, MN,USA)ata1:10 dilution.
TEGplatelet mapping
The contribution of platelet-mediated response to clot strength wasassessedbyTEG measurements based on the TEG ® Platelet Mapping assaykit and TEGanalyser,series 5000,from Haemoscope Corp. (Skokie, IL, USA). Blood from Avertin-anaesthetized ratswas collected in S-monovette lithium-heparintubes by cardiacpuncture. Whole heparinised blood (360 µl) wasadded to aTEG cup containing Activator F(asnakevenomdirectly converting fibrinogen to fibrin without activating the othercoagulation enzymes) and ADP (10 µM, final concentration) or collagen( 20 µg/ml final concentration, Collagenreagent Horm from Nycomed Pharma, Unterschleissheim, Germany).Asparameter forthe clot strength, the maximal amplitude (MA) was measured on the TEGA nalyser.A ll samplesw ere analysed 60-120 min after blood drawing.
Whole blood aggregometry
Foraggregometrymeasurements, blood wassampled fromAvertin-anaesthetized ratsinto S-Monovette citratetubes by cardiac puncture. Samplesof300 µl citrated whole blood were added to 300 µl NaCl/CaCl 2 solution (DynabyteM edical,M unich, Germany)and preheated 3min at 37 o Cintestcells (Multiplate,Dynabyte Medical).Collagen Horm(final concentration 2µg/ml) or ADP (final concentration 5or1µM) in 20 µl wasadded and aggregation measured for6min by impedanceinaMultiplate instrument (Dynabyte Medical).Dataare presented as area under the aggregation curve (AUC). Allsamples were analysed within 120 min after blood drawing.
PRPaggregometry
Heparinized blood (3.6 U/ml) wassampled from the inferior vena cava of EPO-orsaline-treated rats under CO 2 -inducedanaesthesia. PRPwas preparedby10min centrifugation at 400xg.Before aggregation, PRPs amples were incubatedw ith apyrase( 1m U/ml, Sigma #A6535) for9 0m in at 37 o Ct or emove anye xtracellular ADP presentinthe samples. Platelet aggregation wasinduced by addition of either1µMADP or 3µg/mlcollagen,and the aggregatory responsewas measuredovertime by an optical aggregometer (300BD-5, Payton, USA) coupledtoanXctionViewData Acquisition System (SingaT echnology Corporation, Taiwan). Dataa re presented as peak aggregation anda ggregation velocity determined as curve slopesduring onset of the aggregatory response.
Platelet preparation and immunoblotting
Bloodsamples were collected fromthe heartsofAvertin-anaesthetized ratsi nto S-Monovette CTAD tubesa nd were immediatelykept on ice. Forall furthersteps, platelets were kept on ice and centrifugedat4 o C. PRP wasprepared by three rounds of centrifugation at 200xgf or 15, 10 and 3m in, respectively.After each centrifugation,the plasma and buffycoat were transferred to anew vial. Platelets were spun down at 2,000xgfor 5min and resuspended in 400 µl washing buffer (129 mM NaCl, 13.6mM Na 3 -citrate, 11.1mMD-glucose, 1.6mMKH 2 PO 4 ). Remnants of red and white blood cells were removedb ycentrifugation at 200xgfor 75 seconds (s),and platelets were washedtwice before lysis on ice in 1% NonidetP -40,2 0m MT ris-HCl pH 8, 137mMNaCl, 2mMEGTA, 10% glycerol withthe following inhibitors: 1mMNa 3 VO 4 ,50mMNaF,10mMNa-β-glycerophosphate, 1mMAEBSFand protease inhibitor mix Complete (Roche). Thirty µg of protein wasl oadedp er well on 4-12% gradient Bis-Tris NuPAGE gels for SDS-PAGE (Invitrogen). For immunoblotting, the following antibodies were used: anti-P2Y 1 (Sigma,P6487), anti-P2Y 12 (Santa Cruz, sc-27152), anti-phospho-STAT 3( Cell Signaling, MA,U .S.A., #9131), anti-MEK1/2 (Cell Signaling, #9122), anti-GSK3β (Cell Signaling, #9332), anti-β-actin (Sigma, A5441) and horseradish peroxidase-conjugatedsecondaryantibodies (DAKO, Denmark). SeeBlue Plus2 prestainedm olecular weight markers from Invitrogen were included on the blots. Densitometric analyseso fb lots were performedusing the AlphaEaseFC Software.
Bleedingtimeinrats
Rats were anaesthetisedw ith Hypnorm/Dormicum and placed on heating pads throughoutthe experiment to maintain abody temperatureof37 o C. Thetailwas transected 5mmfrom the tip with asingle-usescalpel and the tail wasimmediately immersed into 37 o Cwarmisotonic saline until termination of bleeding was noted. Termination of bleeding wasdefinedasthe timeofcomplete stop of bleeding with no recurrence of bleeding within the next 60 s. No animals exceeded ableeding time of 30 min. Cutofftailtips were subsequently weighedtoensure that therewas no difference in tail cutting between the groups. The treatment groups were blindedfor the observer.
Data presentation
Forh aematological studies, no differences were observedb etween naïve animals and saline-treated controls, therefore only saline-treated controls are shown. DragonEPO and Roche EPO behavedidenticallyinhaematological studies; data in Figure 1 arepresentedfor Epoietin beta (Roche)only. Haemoglobindata completelyp aralleledt he haematocrit data throughout all experiments and therefore is not shown. Data arep resented as means ±SEM and analysedbyone-wayANOVA withBonferroni´s post-hoc test correction using Graph PadP rism 4.02 software. P-values<0.05 were considered statistically significant. Asterisks and "ns"(non-significant) placed above the graph bars denotecomparison to saline group.
Results
Alterationsinblood parameters after short-term EPO treatment Treatment of miceand rats once dailywith EPO (50 µg/kg) for three consecutivedaysincreased RBCcount, reticulocyte count and meanplateletv olume (MPV) when measured 48 hours(h) after the last dosing (Fig. 1) . The increase in RBCand reticulocyte count corresponded to ar ise in haematocrit from 40.9 ± 0.5% (mean ±SEM) to 51.7 ±0.5% in mice, whereas the number of plateletsremained unchanged in both miceand rats (1,322 ± 78 platelets/fl in mice and 1,285 ±195 platelets/fl in rats, mean ±SD, not shown).CEPOtreatment didnot alter anyofthe investigated blood parametersascompared to controls. Furthermore, rats and mice reacted identicallytotreatmentsonall parameters. To test whether acutedosing and handling or the presenceofhigh concentrations of compounds in the sampleshad anyeffect on the haematological endpoints analysed,micew ere treated with EPO,CEPOorsaline for twodaysand blood wasanalysed immediately after the last dose. In this schedule,n od ifferences were detected between the groups (not shown). Alteredwholeblood aggregation responses to ADP and collagenafter EPOtreatment Additional functional platelet parameters were measured as agonist-induced platelet aggregation after short-term treatment with EPO or CEPO.C itrated blood from treateda nimals was subjected to whole blood aggregometrym easurementsa fter stimulation with the plateleta gonistsADP or collagen. As before, rats receivedthreedaily doses of EPO,CEPOorsaline,and blood wasanalysed 48 hafter the last injection. EPO treatment enhanced aggregation in response to collagen, while CEPO had no effect compared to controls (Fig. 5A) . In contrast, the response to ADPw as significantlyimpaired in blood from EPOtreatedr ats ( Fig. 5B) . The effects of EPO on plateletf unction were furtherv alidatedb ye xamining blood from the same animals using TEG plateletm apping. TEGp lateletm apping was performed by stimulating platelets in heparinized whole blood containing afibrin networkinducedbyadirect fibrinogen activator.Thus, this method measuredt he isolatedc ontribution of plateletresponses to clot strength. Using this method, the significantly decreasedADP response in EPO-treated animals wasconfirmed (Fig. 5C) .T oinvestigatewhetherEPO hadany acuteor direct effects on plateletr eactivity,e xperiments were repeated with blood drawn at timepoints 4hand 24 hafter administration of asingle doseofEPO.Inthese acute studies, EPO had no effect on ADP or collageninducedresponses in TEGplateletmapping or whole blood aggregometry( not shown).C EPOd id not influence blood responses in anyofthe aggregometryorTEG analysesp erformed. When analysing blood by standard TEG measurementswith kaolin activation, no differences between the groups were detected (notshown).
AlteredPRP aggregation responses afterEPO treatment
The decreased ADP aggregatory response inducedb yE PO was surprising since ourother dataindicated ageneral platelet hyperreactivity after EPOadministration. To address whether this phenomenoninvolveddesensitization of the ADP receptors, we performed aggregationstudies withADP-depleted PRP in which platelets were allowedtime to resensitize.ADP receptordesensitization occurs as aresponse to lowlevel receptor activationbyextracellular ADP, which mayoriginate fromplatelet granule release or by haemolytic leakageofADP from RBCs.Thus, to eliminate the interference of extracellular ADPinthe aggregationresponse, we isolated PRP from saline-or EPO-treated rats and incubated the samples for 90 min at 37 o Cwith alow concentration of apyrase (1 mU/ml).H eparinized PRP wasu sed for these experiments since apyraseisdependentondivalent cations and therefore does notw orkw ell in citrated samples. The concentration of apyrase waschosentobesufficientlyhightoensurecompletedepletion of adenine nucleotides from plasma (ATP +ADP in plasma is around 100 nM [16] and 1mU/mlapyrasedegrades 1µM/min of AT Pand ADP), buttoo lowtointerfere significantlywith ADP-inducedaggregation. The 90 min incubationat37 o Cwas included to provide sufficient time for the platelet ADP-receptors to resensitize (17) . When challenging the apyrase-treated PRP samples withA DP (1 µM) we found no significant differences between saline and EPO-treated groups in peakaggregation (Fig. 6A )orarea under thea ggregationc urve (not shown). However, after stimulation withcollagen (3 µg/ml) we observed asignificantlyincreasedresponse in the EPO-treated group compared to controls, which was evidenta sa9 5% increasei np eak aggregation ( Fig. 6B )a nd a 350% increaseinaggregationvelocity (Fig. 6C) .
Alterationsinplatelet protein levels afterEPO treatment
In order to investigatew hetherE PO might alterb asic platelet protein composition, we used Westernblot analysis to examine Figure3:Thrombin receptor agonist-inducedplatelet P-selectinsurface expression and sP-selectin plasmalevelsafter treatment withEPO or CEPO. Three groups of animals were injected dailys.c.withsaline,EPO (50µg/kg) or CEPO(50 µg/kg) forthree days and blood samples were collected 48 hafter thelast injection.A)Platelet-poor plasma from micewas analysed by ELISA forlevelsofsP-selectin (n=9-10).B)Citrated blood samples from rats were treated with differentconcentrations of amix of mousethrombin receptorP AR-3 and PAR-4 agonist peptidesand labelledwithantibodiesagainstCD61 (plateletmarker) and CD62P (P-selectin, platelet activationmarker) for flow cytometryanalysis.Activationresulting from simulationwithasubmaximal concentration of agonist peptides(50 µM of each) is shown (n=6). Dotted line represents thebaseline percentage of CD62P + platelets before agonist stimulation(8% forsaline,9%for EPO and CEPO). Data arepresentedasmeans ±SEM. ns =non significant, *=p<0.05, ** =p<0.01.
Figure4
:Dose-dependent effects of EPO on MPVand plasma sP-selectin. Threegroups of animals were injected daily(s.c.) forthree consecutivedayswithEPO (5 or 50 µg/kg) dissolved in saline forrats, or vehicle (saline +0.1% human serumalbumin) formice.Blood samples were collected 48 hafter thelast injection.A)Meanplateletvolume measured in EDTA-stabilised blood from rats,fl=femtoliter (n=8). B) Levels of sP-selectin in platelet-poor plasma from mice, analysed by ELISA (n =9-10).Dataare presented as means ±SEM. ns =non significant, *=p< 0.05, *** =p<0.001.
the levels of variousplateletproteinsinpurified platelets from rats treatedwith three daily doses of EPO or CEPOasdescribed before. Band density analysis revealed thatlevelsofintracellular kinasesM EK1/2 (MAP/ERK kinase) and GSK3β (glycogen synthase kinase-3β)w ere up-regulatedi np latelets from EPOtreated animals, whereas levels of phosphorylatedSTAT3 (signal transducer and activator of transcription 3) were decreased (Fig.  7) .When investigating levels of ERK1/2 (extracellular signalregulatedk inase 1/2),P yk2 (proline-rich tyrosine kinase 2), PI3K (phosphoinositide-3-kinase),S rc, STAT 5o rAkt (protein kinase B), no differencesw ere foundb etween the groups. We also probedthe blots with antibodies against the ADP receptors P2Y 1 and P2Y 12 ,and observedsignificantly increased levels of proteins with the molecular weight of 66 kDaf or P2Y 1 and 45 kDa for P2Y 12 following EPO treatment (Fig. 7) . These bands correspond well to the sizes of transgenically expressed forms of the receptors (18, 19) . However, we cannot excludethat the antibodies recognize other plateletproteinsupregulated by EPOpretreatment of the animals, as the commercially availablea ntibodies lackabsolutespecificity for their cognate P2Y receptors. GAPDH and β-actin were applieda sl oading controls, both yielding similar results.
Bleedingtimeinrats affectedbyEPO butnot CEPO
As am odelf or testing the in-vivo consequences of EPO-mediateda lterations in plateletf unction, bleedingt ime was measuredi nr ats after transection of the tail tip. In thism odel, anti-plateletdrugs such as aspirin andADP receptorantagonists have been shownt op rolong bleedingt ime, indicating that the model is sensitivetoalterations in plateletfunction (20) (21) (22) . Rats were dosed as previouslyd escribed with EPOo rC EPO (50 µg/kg) for three consecutive days,a nd bleedingt ime was measured4 8ha ftert he last dose ( Fig. 8) . EPO treatment decreased bleedingtime to 386±38scompared to 694 ±82sfor saline-treatedc ontrols (mean ±S EM, P<0.05). Bleedingt ime in CEPO-treated rats did not differfrom control group (650 ±126 s).
Figure5:Agonist-induced whole blood aggregatoryresponses after treatmentwithEPO or CEPO. Three groups of rats were injected dailys.c.withsaline,EPO (50µg/kg) or CEPO(50 µg/kg) for threedaysand blood samples were collected 48 hafter thelast injection.A,B)Citrate-stabilised blood samples were stimulatedwitheither 2µg/ml collagen(A) or 5µMADP (B), and aggregationwas measuredby whole blood aggregometry. Graphs showvaluesfor area underthe aggregationcurve (AUC) resulting from integrationofthe aggregationresponse (AU=aggregationunits) over the6min of theanalysis.Abaseline value of AUCwithout agonist was subtracted from all original values (baseline =358 ±136 AU xmin), n=6-12 forAand n=9-16 forB.C: TEGplateletmapping of heparinizedwhole blood stimulatedwith10µM ADP.Clotstrengthisdeterminedbymaximal amplitude (MA) on the TEGanalyser (n =9-12).Dataare presented as means ±SEM. ns =non significant, *=p<0.05, ** =p<0.01, ***=p< 0.001.
Figure6
:Agonist-induced aggregationof apyrase-treated platelet-rich plasma (PRP) from rats. Tw ogroups of rats were injected dailys.c.withsaline or EPO (50µg/kg) forthree days,and blood samples were collected 48 hafter thelast injection.PRP was prepared from heparinizedblood and treated withapyrase before aggregation. Aggregation was induced by either 1µMADP (A) or 3 µg/ml collagen (B-D). A) Peak aggregationvalues above baseline forADP-inducedaggregation. B) Peak aggregationvaluesabove baseline for collagen-inducedaggregation. C) Velocityfor collagen-inducedaggregationdeterminedas thecurve slope at initiation of aggregation. D) Representativeaggregationcurvesfor collagen-inducedaggregationofPRP from EPO and saline-treated rats. AU =aggregationunits, n=8. Data arepresentedasmeans ±SEM. ns =non significant, *** =p<0.001.
Discussion
Thed ata presentedh eres howt hats hort-term,h igh-doset reatmentwith EPOsignificantlyaffected blood parameters andplateletr eactivity, whereas such changesw erea bsenti nC EPOtreated animals.The platelet-alteringeffects of EPO seemed to be relatedtothe high doseof50µg/kg, since5µg/kg did not increase sP-selectin ando nlyp artiallya ffected MPV.This dose-dependency explains whysimilar plateletprofileshavenot been found in previous studieswith EPOinwhichlower doses have been tested. The50µg/kg doseisrelevant for stroketherapy,asitisprotective in mosta nimal models of neuronald amage, andE PO at doses below50µg/kg is suboptimalfor treatmentofbrain ischemia in the rat (23, 24) . Furthermore,dosing of 50 µg/kg EPO in rodents is bioequivalent to the dose of about 5µg/kg tested in humans in asmall clinicalstroke trial (3), taking into accountthe different weight-surface ratio, the 3-4 times extended half-lifeofrecombinant humanEPO in humans compared to rats andthe loweraffinityofhumanEPO for the ratEPO receptor (13, 25, 26 ).
Short-termEPO treatment with 50 µg/kgcaused adramatic rise in haematocrit in rodents, whichwas evident fourdaysafter the first dose, and the haematocrit reached critical levels above 50% (clinicalb loodletting criterion). This potent effect on erythropoiesis is thus an issue in rodentsafter only three dosesof EPO, and haematopoietic side effectsmay be even moreprominent if EPO is to be usedinlong-term dosing schedules as might be relevant in chronic neurologicaldisorders. In arecent clinical trialw ith non-anaemic schizophrenicp atients, eighto ut of 20 EPO-treatedpatients required bleeding at leastonce during the threem onths experiment to reduce haematocrit, although patients received about 5µg/kg EPO onlyonce aweek (4).
EPOf urthermore caused an increase in MPVi nr odents, whichisconsistent with findings in patients with chronic renal failure, butwhich has not earlier beenfound in healthyindividuals (27).Inhumans, an increased MPViscorrelated to aw orsenedoutcome after cerebrovascularand cardiovasculare vents as well as to an increased risk of recurrent eventsofmyocardial infarctions and stroke (28) (29) (30) . MPVmay therebybeaclinically relevant markero fr isks associatedw ith thrombotic events. In addition, EPO treatment increased plasmalevelsofsP-selectin, in accordance with findings in healthyhuman individuals (10) . The soluble formofP-selectinisshed from platelets after P-selectin surfaceexposure,and it is itself abiologically activeprotein, whichenhances clot formation and fibrin deposition (31) . An increased plasma levelo fs P-selectin hasb een observed in acutestrokepatients and is associatedtovariouspro-thrombotic conditions,such as atrial fibrillation and atherosclerosis (11, 32, 33) .
Blood from animals pre-treatedw ith EPO exhibited increased platelets ensitivity to thrombin receptor agonist peptides, as well as an increased aggregation response to collagen stimulation compared to platelets from saline-treated controls. In contrast, the plateletADP-mediated response wasm arkedly reduced by EPOtreatment,showing a50% reduction in the TEG plateletmapping assay. The fact thatthe decreasedaggregatory response to ADPwas no longer observed in apyrase-treated PRP, whichwas allowedtorestinthe absence of ADP,indicates that desensitization of plateletADP receptors is alikelyexplanation for the phenomenon observedinwhole blood. This seems even morelikelyinthe light of our finding that the collagenresponse of PRP from EPO-treated animals wass ignificantly enhanced, and the extent of enhancement appeared larger in apyrase-treated PRP than in whole blood aggregometry. Apossible explanation for this could be that collagen-induced aggregation is acomposite response reflecting both the isolatedc ollagen-response and the reaction to secondarilyr eleased ADP (34) .T hus, normalisation of the ADP response in apyrase-treatedPRP mayhaverevealed the true effect of EPOonthe plateletcollagen response. The desensitization of plateletADP receptors couldresultfrom low-levelg ranule releasef rom circulating platelets leading to local increases in ADPlevelswhich in turnactivatesand desensitizesp lateletA DP receptors throughi nternalization either in vivo or in vitro (35) .Alternatively, the higher numberofRBCs in EPO-treated animals mayincrease plasmatic ADP levels since adenosine phosphatecompounds arereleased fromRBCs both during normal physiologically responses in vivo and during haemolysis as mayoccur in vitro after blood sampling (36) .However,the 50% decrease in ADP response observedinTEG platelet mapping suggests that the increase in RBCnumber is unlikelytobethe sole contributor to desensitization.
The increased protein levels observedi nW estern blotting with antibodies against the ADP receptors P2Y 1 and P2Y 12 may indicate the presenceofacounter-regulatorymechanism against ADP-receptor desensitization, possibly allowingplatelets to increaseADP-receptorl evelsb yt ranslationalc ontrol. Also proteins involved in intracellularpathwayswere regulatedbyEPO, including alterationsi nt he levels of MEK1/2, GSK3β and phospho-STAT 3, whicha re all involved in potentiation of plateletaggregation. TheMAPKpathway involving MEK1/2 is responsiblef or production of thromboxane A 2 after ADP stimulation (37) and STAT 3isinvolved in increasing plateletreactivity after thrombin stimulation (38) . Therole of GSK3β is largely unknown, butinhuman platelets, inhibition of GSK3β abrogates collagen-induced aggregation (39) . Thedirect consequences of these modifications in plateletp rotein levels are yetu nknown, buttheyindicate that EPO treatment has aclear effect on basic platelets composition. We suspect thatalterationsinplatelet-protein composition maybepartlyresponsible for changes in plateletreactivity.Elucidation of otherproteinsregulated by EPO (i.e. by proteomics approach) could help produceamore complete picture of the cause and consequencerelationship between high-doseEPO treatment and platelet reactivity.
AlthoughEPO treatment resultedinacomplexaggregatory profile with increased responses to thrombin receptor agonist peptidesa nd collagena ccompaniedb ya na ttenuation of the ADP-responseinwhole blood,the bleeding time studyconfirmed that in-vivo clot formation wasenhanced by EPOtreatment. Fewstudieshaveinvestigated compounds whichdecreasebleeding time in normalanimals, butincreased bleeding time in the rat tail transection modelcorrelates well with adecreased thrombus formation in in-vivo thrombosis models (40, 41) .
ChangesinMPV and platelet reactivity manifestedonlyfour days after the initial dose, and were notp resenta te arliert ime points tested. Furthermore,in-vitro stimulation of whole blood with high concentrations of EPO did not induce shedding of sPselectin, nor did it alter ADP-or collagen-induced aggregation (notshown).Therefore,itseemsfeasible thatEPO does notexert direct effects on circulating platelets, butrather modulatesplatelets during synthesis and maturation in the bonem arrow. Megakaryocytespossess high affinity binding sites for EPO and EPO affects these cells directly, causing an increase in megakaryocyte sizeand number both in vitro and in vivo (42, 43) . This propertyofEPO is likelytoe xplain our observations on MPV, sinceplateletsizeisdeterminedatthe timeofsynthesis and is therebyd ependento nm egakaryocyte volume (44) . It has been hypothesized, basedo ns tudiesi nh umans and dogs, that EPO treatment mediatesanincreased plateletturnover, thus involving an increased production of newa nd more reactive platelets as well as apremature loss of circulating platelets (9, 45, 46) . Additionally, EPOtreatment causes adecreaseinthrombin EC 50 values forplateletactivation, correlating to young platelets having a decreasedthrombin EC 50 comparedtoolderplatelets (9, 45, 47) . It is likelythat the changes in plateletreactivity observedinthis study,are aresultofEPO-induced synthesis of newplatelets exhibiting altered agonist responses, possibly due to alterations in expression of receptors and intracellular signalling proteins. In summary, short-term treatment with EPO at dosesoptimal for neuroprotection caused significant alterationsi np lateletf unction and composition with in-vivo haemostatic consequences. In contrast, CEPOt reatment had no effect on these parameters. Thus,CEPOseemstobedevoid of anyobvious haemostatic effects, thereby supporting arecent study showing thatwhile EPO causes an acute rise in blood pressure in rats, CEPO, in contrast, doesnot (48) .Animal studies have shown thatEPO and EPO-derivedcompounds mayhavethe potential to bring benefitfor both embolic and haemorraghic strokep atients (49,5 0) . In both forms of CNS injury, it is important to treat haemostatic disturbances to avoid recurrent cerebrovasculare vents. The use of a stroket herapeutic, whicha lters elementso fh aemostatic function mayinterfere with the function of other anti-or pro-thrombotic drugs administered to patients, therebycomplicating clinicalm anagement of these patients. Therefore, EPOd erivatives suchasCEPO, withneuroprotectivepotential and devoid of haemostatic effects, maybebeneficialasnovel therapeuticsinthe treatment of stroke.
